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Abstract
Background: IL-12p40 plays an important role in the activation of the T-cell lines like Th17 and Th1-cells. Theses
cells are crucial in the pathogenesis of juvenile idiopathic arthritis. A polymorphism in its promoter region and the
genotype IL12p40 pro1.1 leads to a higher production of IL-12p40. We studied whether there is a difference in the
distribution of the genotype in patients with JIA and the healthy population.
Methods: In 883 patients and 321 healthy controls the IL-12p40 promoter genotype was identified by ARMS-PCR.
Results: There is no association of IL-12p40 pro polymorphism neither in patients with JIA compared to controls
nor in subtypes of JIA compared to oligoarthritis. We found a non-significant tendency of a higher prevalence of
the genotype pro1.1 in systemic arthritis (32.4 %) and in rheumatoid factor negative polyarthritis (30.5 %) and a
lower pro1.1 genotype in persistent oligoarthritis (20.7 %) and in enthesitis-related arthritis (17 %). Likelihood of the
occurrence of genotype IL12-p40 pro1.1 in patients with systemic arthritis (OR 1.722, CI 95 % 1.344-2.615, p 0.0129)
and RF-negative polyarthritis (OR 1.576, CI 95 % 1.046-2.376, p 0.0367) compared to persistent oligoarthritis was
significantly higher. This was also true for comparison of their homozygous genotypes IL-12p40 pro 1.1 and 2.2 in
systemic arthritis (OR 1.779, CI 95 % 1.045-3.029, p 0.0338). However, in Bonferroni correction for multiple hypothesis
this was not significant.
Conclusion: A tendency of a higher prevalence of the genotype IL-12p40 pro1.1 in systemic arthritis and in
rheumatoid factor negative polyarthritis was observed but not significant. Further investigations should be done
to clarify the role IL-12p40 in the different subtypes of JIA.
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Background
Juvenile idiopathic arthritis (JIA) is a disease of unknown
origin. Genetically susceptible individuals develop arth-
ritis triggered by exposition to environmental factors
which leads to an uncontrolled response to self-antigens.
These antigens induce an initial B- or T-cellular immune
reaction which results in an immune response including
secretion of TNF-a, IL-6 and IL-12 and the induction
and activation of Th17 and Th1 cells. JIA affects about
2-20/100000 children/year and is classified according to
the ILAR criteria (International League of Associations
for Rheumatology) into different subtypes such as oli-
goarthritis, polyarthritis, systemic arthritis and arthritis
with associated psoriasis or enthesitis (see reference [1]
Prakken et al. for review).
Serum levels of IL-12 are higher in patients with JIA
compared to healthy controls and in particular in pa-
tients with systemic arthritis and polyarthritis. In these
patients serum levels of IL-12 are also significantly
higher in acute and in inactive state than in patients with
* Correspondence: ktenbrock@ukaachen.de
12Department of Pediatrics, Division of Pediatric Pneumology, Allergology
and Immunology, RWTH Aachen, University, Pauwelsstr 30, D-52074 Aachen,
Germany
Full list of author information is available at the end of the article
© 2015 Eberhardt et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Eberhardt et al. Pediatric Rheumatology  (2015) 13:61 
DOI 10.1186/s12969-015-0059-z
oligoarthritis [2] and strikingly higher compared to healthy
controls (about 5 fold elevation). Gattorno et al. have
shown that it is particularly the subunit IL-12p40 and not
the total IL-12 concentration that is elevated in patients
with JIA. IL-12p40 expression by activated B cells has also
been documented in the inflamed joints of JIA patients
[3]. While patients with polyarthritis or oligoarthritis in
remission do not differ from healthy controls [4], serum
levels of IL-12 are still found elevated in patients with
systemic arthritis in remission.
IL-12p40 is encoded on Chromosome 5q31–33 [5],
produced mainly by macrophages, neutrophils, microglia
and dendritic cells [6] and promotes in cooperation with
IL-12p35 (as IL-12p70) the induction and activation of
Th1-cells while it promotes in cooperation with IL-23p19
(as IL-23) the induction and activation of Th17-cells, both
key elements in the pathophysiology of JIA. An insertion/
deletion polymorphism in the promoter region of IL-12p40
((GC/(GC) del(CTC TAA)ins); rs17860508 [5]) with its two
alleles IL-12p40 pro1 and IL-12p40 pro2 has an influence
on the expression of IL-12p40: The genotype IL-12p40
pro1.1 leads to a higher production of IL-12p40 from
PBMC in silicosis patients [7], in asthma patients [8]
and in dendritic cells of healthy donors, the latter
however showing no elevated secretion of IL-12p70
[9]. Given the importance of IL-12p40 in the induction
of Th1 and Th17 cells and the possible importance in
the pathogenesis of JIA, we hypothesized that the re-
partition of the IL-12p40 pro-genotype is different in
children affected by JIA from healthy controls and in-
between subtypes. Since this 6 bp insertion/deletion
polymorphismus is not regularly tested on whole gen-
ome SNP arrays, it has not yet been identified as being
important.
Methods
Patients
Blood DNA samples of 883 patients with juvenile idiopathic
arthritis (180 with polyarthritis, 469 with oligoarthritis, 139
with systemic arthritis, 29 with psoriasis related, 52
with enthesitis related arthritis and 14 with unspecific
JIA) have been collected in 3 German paediatric rheuma-
tology departments (673 patients from the German Center
of paediatric rheumatology, Garmisch–Partenkirchen,
Department of Pediatrics, University Hospital Tübingen,
Olgahospital Stuttgart and St Josef Stift Sendenhorst, 134
patients from the University Hospital Würzburg, 76 pa-
tients from the University Hospital Dresden). Blood DNA
samples of 321 healthy subjects, unmatched for age and
sex but all Caucasians from Germany, were from depart-
ment of Humangenetik RWTH Aachen. Ethical approval
of local institutions and informed consent according to
the Declaration of Helsinki was obtained.
PCR
Genotyping was performed by amplification refractory
mutation system PCR (ARMS-PCR). The IL-12p40 pro-
moter region was screened for two different already de-
scribed alleles (GC/(GC) del(CTC TAA)ins) (rs17860508
[5]). The longer allele IL-12p40 pro1 is detected by the
specific primer IL-12p40 5–8 (TGT CTC CGA GAG
AGG CTC TAA), the 4 bp shorter allele IL-12p40 pro2
by IL-12p40 5–10 (TGT CTC CGA GAG AGG GCT
GT). As generic 3′ primer IL12p40 3–5 (TGG AGG AAG
TGG TTC TCG TAC) was used for both reactions
(Primers from Eurogentec, Cologne, Germany). As control
primers derived from the C reactive protein-gene CRP 3
and 5 were employed (CRP 3: CCA GCC TCT CTC ATG
CTT TGG TTG GCC AGA CAG, CRP5: GGG TCG
AGG ACA GTT CCG TGTAGA AGT GGA).
The reaction mix contained 10–20 ng genomic DNA,
1x PCR Buffer (Qiagen, Hilden, Germany, containing
15 mM MgCl2), 1.5 μl MgCl2 (25 mM), 0.5 μl dNTP
10 mM, 1U Top Taq DNA Polymerase (Qiagen Hilden,
Germany), 5 pmol of each IL-12p40 primers and 2.5
pmol of each CRP primer. Taq activation was performed
by an initial step of 95 °C (15 min), followed by 35 cycles
(94 °C for 30s, 65 °C for 30s, 72 °C for 30s). PCR prod-
uct was visualized in a 2.5 % agarose gel with 0.01 %
ethidium bromide.
Statistics
Chi-square test (3x2) and two-sided Fisher’s t-test were
performed using Prism 5.0 GraphPad software. P-values
were considered significant when < 0.05, Odds ratios are
cited with their 95 % confidence interval (CI). Bonferroni
correction of the p-value was performed for multiple
hypothesis testing. P-values were considered significant
when < 0.008.
Results
No significant association of IL-12p40 pro polymorphism
in patients with JIA compared to healthy subjects
A genotyping of the IL-12p40 pro polymorphism was
performed in 883 patients with JIA and in 321 healthy
controls.
There was neither a significant difference in the oc-
currence of the IL-12p40 promoter genotype nor in the
distribution of alleles (see Table 1). Noteworthy is a
clear but non-significant tendency of a higher prevalence
of the genotype 1.1 in systemic arthritis (32.4 %) and
in rheumatoid factor negative polyarthritis (30.5 %). In
addition we found a clearly lower pro1.1 genotype
(21.75 %) in favour of a high IL-12p40 pro2.2 genotype
(25.8 %) in oligoarthritis, the same was true in enthesitis-
related arthritis but here in favour of a higher IL-12p40
pro1.2 genotype (61 %). However there was no significant
different distribution of genotypes between all JIA patients
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or the subtypes of JIA compared to healthy controls
(Table 1).
No significant association of the predominant genotype
IL-12p40 pro1.1 in patients with systemic arthritis and
polyarthritis compared to oligoarthritis
Comparing the genotypes IL-12p40 pro1.1 and IL-12p40
pro2.2 of patients with oligoarthritis to other all other
subtypes of JIA there was no significant difference in
distribution. The significantly higher IL-12p40 pro1.1
genotype seen in systemic arthritis or polyarthritis
versus oligoarthritis in single comparison did not re-
main significant when tested for multiple comparison
with the Bonferroni method (p 0.011 for systemic
arthritis, p 0.03 for polyarthritis RF negative; p signifi-
cant < 0.008).
Table 1 Distribution of genotypes IL-12p40 pro 1.1, IL-12p40 pro 1.2, IL-12p40 pro 2.2 and of alleles IL-12p40 pro 1 and IL-12p40
pro 2 in patients with a subtype of JIA and healthy controls (absolute number and percentage), all in Hardy-Weinberg equilibrium
No of patients (% of JIA) IL-12 p40 pro1.1 IL-12 p40 pro1.2 IL-12 p40 pro2.2 Chi2-test p-value
Polyarthritis RF positive 29 (3.3 %) 6 (20 %) 12 (41 %) 11 (37.9 %) 0.2306
Polyarthritis RF negative 151 (17.1 %) 46 (30.46 %) 70 (46.36 %) 35 (23.17 %) 0.7842
Systemic arthritis 139 (15.7 %) 45 (32.4 %) 64 (46.0 %) 30 (21.6 %) 0.556
Oligoarthritis 469 (58.1 %) 102 (21,75 %) 246 (52.45 %) 121 (25,8 %) 0.1866
Psoriasis-related arthritis 29 (3.3 %) 7 15 7 0.92
Enthesitis-related arthritis 52 (5.9 %) 9 (17 %) 32 (61 %) 11 (21 %) 0.1932
Undifferentiated arthritis 14 (1.6 %) 4 7 3
All patients with JIA 883 219 (24.8 %) 446 (50.5 %) 218 (24.7 %) 0.654
Healthy individuals 321 88 (27.4 %) 157 (48.9 %) 76 (23.7 %)
Allele pro 1 JIA 884 (50.1 %) 0.432
Healthy Controls 333 (51.9 %)
Allele pro 2 JIA 882 (49.9 %)
Healthy Controls 309 (48.1 %)
Chi-square test was performed between subtypes and healthy controls
Fig. 1 Forest plots of OR and its 95 % CI: Relation of homozygous genotypes pro 1.1 (a) and pro2.2 (b) between subtypes of JIA and
oligoarthritis. Comparison of distribution of genotype IL-12p40 1.1 vs 2.2 between JIA and healthy subjects (c) and between subtypes of
JIA and Oligoarthritis. The depicted significant Odds-ratios were not significant in Bonferroni analysis, that requires p < 0.008
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By pooling the genotypes IL-12p40 pro1.2 and 2.2, we
tested an association of IL-12p40 pro1.1 in systemic
arthritis or polyarthritis versus oligoarthritis. The likeli-
hood of the occurrence of genotype IL-12p40 pro1.1 in
patients with systemic arthritis and RF-negative polyar-
thritis is nearly twice as high as in oligoarthritis (Fisher’s
t-test for systemic arthritis: OR 1.722, CI 95 % 1.134-2.615,
p 0.011, for polyarthritis RF negative OR 1.576, CI 95 %
1.046-2.376, p0.03, Fig. 1a). Testing of the homozygous
genotypes IL-12p40 pro1.1 and pro2.2 substantiated
this finding: the likelihood of prevalence of IL-12p40
pro 1.1 was 1.8 times higher in systemic arthritis (OR
1.779, CI 95 % 1.045 -3.029, p 0.034) but not for RF
negative polyarthritis (OR 1.559 CI 95 % 0.934-2.603, p
0.089) compared to the distribution in oligoarthritis
(Fig. 1c + d). However, again in Bonferroni correction
for multiple comparison this did not remain significant
(p < 0.008).
Furthermore, there was no association for the genotypes
of children with other subtypes of JIA and oligoarthritis,
neither for the genotype IL-12p40 pro2.2 (Fig. 1b) nor for
rheumatoid factor negative and positive polyarthritis
(Chi2-Test p 0.22).
Discussion
The present study is the first to investigate the functional
relevant IL-12p40 promoter polymorphism in children
with JIA. There was a tendency but no clear evidence for
an association between the genotypes of patients with JIA
or its subgroups and healthy controls.
Regarding the genotypes of the control subjects, in this
group genotype IL-12p40 pro1.1 was more frequent than
genotype IL-12p40 pro2.2. In several European studies
either type IL-12p40 pro1.1 was less frequent than pro2.2
(20 % versus 22-31 % [10, 11]) or nearly equal (24 % versus
26 % [8]), in other surveys type pro1.1 was more common
than IL-12p40 pro2.2 (30-35 % for type pro1.1 and 15-
20 % for type pro2.2, mainly Bulgarian patients [7, 12]).
These somewhat mixed results are likely influenced by
the high impact of the geographical origin and the num-
ber of tested individuals on the genotype’s distribution.
In this study the latter factor is statistically limiting.
Therefore no tribute was paid to the lower prevalence of
the IL-12p40 pro1.1 genotype in patients with oligoar-
thritis compared to the here tested healthy subjects since
most of the European study controls have similar per-
centages of the pro 1.1-genotype.
A tendency of a more frequent genotype IL-12p40
pro1.1 in systemic and polyarticular arthritis compared
to oligoarthritis could not be proven significant in mul-
tiple comparison testing. This is partially due to the low
number of samples in the subgroups of systemic and
polyarticular arthritis. Control studies in other populations
are needed to definitively exclude any association of
the here tested genotypes of the promoter of IL-12p40
with JIA.
Given the heterogeneity of the subgroups of JIA and
the supposition of their different aetiologies [13], it is
still possible that IL-12p40 is an important element in
the pathogenesis of systemic and polyarticular arthritis.
This is supported by studies showing a high level of IL-12
respectively IL-12p40 in the serum of patients with these
two diseases in contrast to other subtypes [2, 4]. Analogic-
ally this does apply for patients with rheumatoid arthritis
where no association of the IL-12p40 promoter genotype
had been found [14]: In their synovial fluid the con-
centration of IL-12p40 was not elevated in contrast to
JIA-polyarthritis and juvenile enthesitis-related arthritis
[15]. Furthermore in autoimmune arthritis the presence of
IL-12 is necessary to convert Th17 cells in vitro into
Th17/1 cells [16]. This shift correlates with higher param-
eters of inflammation in patients with oligoarticular-onset
JIA [17]. Therefore our primary assumption was that pa-
tients with oligoarthritis might have a higher prevalence of
the IL-12p40 pro1.1 genotype. However this was not the
case and might be related to the fact that the IL-12p40
pro1.1 phenotype does not necessarily result in an en-
hanced IL-12p70 production, which is needed for the
conversion of Th17 into Th1 cells.
Therefore further studies are necessary to elucidate the
exact role of IL-12p40 in JIA and its different subtypes.
Conclusion
No clear association between the polymorphisms of the
IL-12p40 promotor of JIA patients or their subtypes
could be found. Control studies in other populations are
needed to definitively exclude any association and further
studies should be done to evaluate the exact function of
IL-12p40 in JIA.
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